AR022017A1 - AN AGENT TO TREAT THE DISORDER OF THE FUNCTION OF VISUAL CELLS. THE METHOD OF TREATMENT AND THE USE OF SUCH AGENT FOR THE PRODUCTION OF A PHARMACEUTICAL COMPOSITION - Google Patents

AN AGENT TO TREAT THE DISORDER OF THE FUNCTION OF VISUAL CELLS. THE METHOD OF TREATMENT AND THE USE OF SUCH AGENT FOR THE PRODUCTION OF A PHARMACEUTICAL COMPOSITION

Info

Publication number
AR022017A1
AR022017A1 ARP990106748A ARP990106748A AR022017A1 AR 022017 A1 AR022017 A1 AR 022017A1 AR P990106748 A ARP990106748 A AR P990106748A AR P990106748 A ARP990106748 A AR P990106748A AR 022017 A1 AR022017 A1 AR 022017A1
Authority
AR
Argentina
Prior art keywords
agent
treatment
disorder
treat
production
Prior art date
Application number
ARP990106748A
Other languages
Spanish (es)
Original Assignee
Sucampo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Pharmaceuticals Inc filed Critical Sucampo Pharmaceuticals Inc
Publication of AR022017A1 publication Critical patent/AR022017A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se revela un agente para el tratamiento del trastorno de la funcion de las células visuales que contiene un inhibidor de interleucina 2 tal como uncompuesto macrolido, particularmente FK506. Se describe además, el uso de dicho inhibidor para la preparacion de composiciones farmacéuticas.An agent for the treatment of visual cell function disorder is disclosed that contains an interleukin 2 inhibitor such as a macrolide compound, particularly FK506. The use of said inhibitor for the preparation of pharmaceutical compositions is also described.

ARP990106748A 1998-12-24 1999-12-23 AN AGENT TO TREAT THE DISORDER OF THE FUNCTION OF VISUAL CELLS. THE METHOD OF TREATMENT AND THE USE OF SUCH AGENT FOR THE PRODUCTION OF A PHARMACEUTICAL COMPOSITION AR022017A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11393998P 1998-12-24 1998-12-24

Publications (1)

Publication Number Publication Date
AR022017A1 true AR022017A1 (en) 2002-09-04

Family

ID=22352417

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990106748A AR022017A1 (en) 1998-12-24 1999-12-23 AN AGENT TO TREAT THE DISORDER OF THE FUNCTION OF VISUAL CELLS. THE METHOD OF TREATMENT AND THE USE OF SUCH AGENT FOR THE PRODUCTION OF A PHARMACEUTICAL COMPOSITION

Country Status (13)

Country Link
EP (1) EP1140134A1 (en)
JP (1) JP2002542150A (en)
KR (1) KR20010099928A (en)
CN (1) CN1224420C (en)
AR (1) AR022017A1 (en)
AU (1) AU781049B2 (en)
BR (1) BR9917113A (en)
CA (1) CA2356382A1 (en)
MX (1) MXPA01006449A (en)
NO (1) NO20013146L (en)
NZ (1) NZ513111A (en)
TW (1) TW546145B (en)
WO (1) WO2000038703A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
AU2003209297A1 (en) 2002-01-18 2003-09-02 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
DK1539157T3 (en) 2002-09-18 2013-10-07 Univ Pennsylvania METHOD OF INHALING CHOROIDAL NEOVASCULARIZATION
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
KR20060085246A (en) 2003-09-18 2006-07-26 마커사이트, 인코포레이티드 Trans scleral delivery
DK1848431T3 (en) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
US7592330B2 (en) 2005-08-08 2009-09-22 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
KR20140093764A (en) 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 Stable formulations, and methods of their preparation and use
ES2563288T3 (en) 2006-03-23 2016-03-14 Santen Pharmaceutical Co., Ltd Rapamycin in low doses for the treatment of diseases related to vascular permeability
US20210338770A1 (en) * 2018-10-15 2021-11-04 Osaka University Medicament for improving or preventing symptoms relating to retina and/or light reception and method for screening for substance capable of improving or preventing symptoms relating to retina and/or light reception

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003049A1 (en) * 1990-08-23 1992-03-05 New York University Methods and compositions for treating t-cell mediated diseases
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
AU727080B2 (en) * 1997-06-30 2000-11-30 Allergan, Inc. Calcium blockers to treat proliferative vitreoretinopathy
CZ287497B6 (en) * 1997-12-30 2000-12-13 Galena, A. S. Topic eye preparations containing immunosuppressive substances
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders

Also Published As

Publication number Publication date
NO20013146D0 (en) 2001-06-22
WO2000038703A1 (en) 2000-07-06
AU1690600A (en) 2000-07-31
KR20010099928A (en) 2001-11-09
TW546145B (en) 2003-08-11
CN1224420C (en) 2005-10-26
AU781049B2 (en) 2005-05-05
MXPA01006449A (en) 2002-04-24
JP2002542150A (en) 2002-12-10
BR9917113A (en) 2001-10-23
NZ513111A (en) 2003-10-31
CN1352565A (en) 2002-06-05
CA2356382A1 (en) 2000-07-06
NO20013146L (en) 2001-08-20
EP1140134A1 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
ES2128552T3 (en) COMBINATION OF AN INHIBITOR OF THE BIOSYNTHESIS OF CHOLESTEROL AND AN INHIBITOR OF THE ABSORPTION OF BETA-LACTAMA CHOLESTEROL.
MX9202407A (en) PHARMACEUTICAL COMPOSITION CONTAINING AN ALYLAMINE COMPOUND AS THE ACTIVE AGENT AND PROCESS FOR ITS PREPARATION.
ECSP941104A (en) DERIVATIVES OF 2,6 DIAMINOPURINE, PROCEDURE FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
AR007827A1 (en) 3-UREIDO-PIRIDOFURANOS y -PIRIDOTIOFENOS, PROCEDURE FOR ITS PREPARATION, COMPOSITION THAT UNDERSTANDS THEM AND USE OF SUCH COMPOUNDS FOR THE PREPARATION OF MEDICINES.
ATE370730T1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING CHELATING/SEQUESTING AGENTS AND THEIR DERMATOLOGICAL USE
BR0111206A (en) Arylmethylamine derivatives for use as tryptase inhibitors
ES2044912T3 (en) PHARMACEUTICAL COMPOSITIONS EQUIPPED WITH SEQUESTRATING ACTIVITY FOR BILIARY ACIDS, CONTAINING CHOLESTIRAMINE AS AN ACTIVE SUBSTANCE, AND PROCEDURE FOR ITS PREPARATION.
ES2176502T3 (en) USEFUL HYDROXYLAMINE DERIVATIVES TO IMPROVE THE PPRODUCTION OF MOLECULAR CHAPERONS ITS PREPARATION.
AR018357A1 (en) PETROSELINIC ACID IN A COMPOSITION AND IN A METHOD TO REDUCE OR ELIMINATE THE IRRITATION OR THE PICAZON OF THE SKIN INDUCED BY ALFA-HYDROXIACIDES
AU7023987A (en) Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
ES2126766T3 (en) TROPYL 7-AZAINDOL-3-ILCARBOXIAMIDES AS ANTI-TUSSIVE AGENT.
AR023807A1 (en) AN AGENT TO TREAT DRY EYE AND USE A MACROLID COMPOUND TO PREPARE PHARMACEUTICAL COMPOSITIONS FOR DRY EYE TREATMENT
ES2052603T3 (en) DERIVATIVES OF BENCIMIDAZOLE, PROCEDURE FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITION THAT CONTAIN THEM.
BR0311460A (en) Modified release pharmaceutical composition, use of a formulation, and method for treating a cardiovascular disorder in a patient
BRPI0407652A (en) method for enhancing the effectiveness of an active agent, composition and method for producing the composition
AR022017A1 (en) AN AGENT TO TREAT THE DISORDER OF THE FUNCTION OF VISUAL CELLS. THE METHOD OF TREATMENT AND THE USE OF SUCH AGENT FOR THE PRODUCTION OF A PHARMACEUTICAL COMPOSITION
HUP9602498A2 (en) Pharmaceutical compositions of antimicrobial activity
BR0109672A (en) Use of zd6126 or a pharmaceutically acceptable salt thereof and one of: a plantin antitumor agent and a taxane, pharmaceutical composition, combination product, kit, and method for producing a vascularly damaging effect on a warm-blooded animal
DE69919597D1 (en) TOPICAL FORMULATIONS CONTAINING SKIN PENETRATION AGENTS AND THEIR USE
AR019327A1 (en) COMBINATION OF FENTOLAMINE AND APOMORPHINE FOR THE TREATMENT OF HUMAN SEXUAL FUNCTION AND DYSFUNCTION
AR028987A1 (en) COMPOSITE DERIVED FROM CYCLOPENTAPIRIDIN-KETONE, PHARMACEUTICAL COMPOSITION CONTAINING IT AND ITS USE IN THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT TO TREAT A DISEASE
ES2189206T3 (en) BETA-ALCOXIACRYLATES AGAINST MALARIA.
ES2153584T3 (en) PIRIDINIMINIL-1,2-BENZISOXAZOL AND -BENZISOTIAZOL AS ANTIPSYCHOTICS.
ES2031462T3 (en) PROCEDURE TO PRODUCE 1-B-D-ARABINOFURANOSILCITOSINA-5'-STERARILFOSFATO MONOSODICO AND MONOHIDRATO OF THE SAME, AND PHARMACEUTICAL COMPOUND THAT CONTAINS THIS LAST.
BR9709989A (en) Processes for treating a plant disease, for preparing a substance or composition for treating plant disease and for fertilizing a plant, for fertilizing a plant, substances or compositions for treating a plant disease and for fertilizing a plant plant, and their use.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal